New combo therapy shows promise for Hard-to-Treat colon cancer
NCT ID NCT03712943
First seen Nov 14, 2025 · Last updated May 22, 2026 · Updated 21 times
Summary
This early-phase study tested the safety and best dose of two drugs—regorafenib and nivolumab—given together to people with advanced colorectal cancer that has not responded to standard treatments. The cancer type studied is mismatch repair proficient, meaning it does not have a specific DNA repair defect. The goal was to find a tolerable dose and see if the combination can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.